Summit Therapeutics Plc Stock Performance
| SMMT Stock | USD 18.94 0.26 1.35% |
On a scale of 0 to 100, Summit Therapeutics holds a performance score of 8. The entity has a beta of 2.92, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Summit Therapeutics will likely underperform. Please check Summit Therapeutics' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Summit Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Summit Therapeutics PLC are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak primary indicators, Summit Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.35) | Five Day Return 2.38 | Year To Date Return 617.42 | Ten Year Return 85.87 | All Time Return 85.87 |
Last Split Factor 1:1 | Last Split Date 2020-09-21 |
1 | This Company Generates No Revenue and Its Market Cap Is Over 20 Billion. Heres Why That Valuation May Not Be All That Ridiculous. | 09/18/2024 |
2 | Acquisition by Mahatme Ujwala of 40500 shares of Summit Therapeutics at 1.67 subject to Rule 16b-3 | 09/20/2024 |
3 | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 10/04/2024 |
4 | Acquisition by Clark Kenneth A of 200000 shares of Summit Therapeutics at 19.95 subject to Rule 16b-3 | 10/11/2024 |
5 | Summit Therapeutics Trading Up 0.8 percent Heres What Happened | 10/21/2024 |
6 | Summit Therapeutics Set to Announce Earnings on Wednesday | 10/29/2024 |
7 | Decoding Summit Therapeutics Inc A Strategic SWOT Insight | 10/31/2024 |
8 | Summit Therapeutics Unique Investment In Oncology, Lead Drug Candidate Shows Promise Over Keytruda And Opdivo | 11/04/2024 |
9 | Huge discounting drives surge in electric car demand as petrol sales plunge | 11/05/2024 |
10 | Summit Therapeutics Has Debt But No Earnings Should You Worry | 11/08/2024 |
11 | Significant Stake Increase by Baker Bros. Advisors in Nurix Therapeutics | 11/15/2024 |
12 | Alarm bells ringing as EV transition hits UK auto industry | 11/27/2024 |
| Begin Period Cash Flow | 648.6 M |
Summit |
Summit Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,298 in Summit Therapeutics PLC on August 30, 2024 and sell it today you would earn a total of 596.00 from holding Summit Therapeutics PLC or generate 45.92% return on investment over 90 days. Summit Therapeutics PLC is currently generating 0.9778% in daily expected returns and assumes 9.6009% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of stocks are less volatile than Summit, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Summit Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Summit Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Summit Therapeutics PLC, and traders can use it to determine the average amount a Summit Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1018
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SMMT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.6 actual daily | 85 85% of assets are less volatile |
Expected Return
| 0.98 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Summit Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Summit Therapeutics by adding it to a well-diversified portfolio.
Summit Therapeutics Fundamentals Growth
Summit Stock prices reflect investors' perceptions of the future prospects and financial health of Summit Therapeutics, and Summit Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Summit Stock performance.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 13.51 B | ||||
| Shares Outstanding | 737.45 M | ||||
| Price To Earning | 2.85 X | ||||
| Price To Book | 31.89 X | ||||
| Price To Sales | 753.90 X | ||||
| Gross Profit | 705 K | ||||
| EBITDA | 1 M | ||||
| Net Income | (614.93 M) | ||||
| Cash And Equivalents | 121.97 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 106.1 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | 0.59 X | ||||
| Cash Flow From Operations | (76.76 M) | ||||
| Earnings Per Share | (0.23) X | ||||
| Market Capitalization | 13.97 B | ||||
| Total Asset | 202.95 M | ||||
| Retained Earnings | (993.26 M) | ||||
| Working Capital | 169.31 M | ||||
| Current Asset | 20.86 M | ||||
| Current Liabilities | 3.21 M | ||||
About Summit Therapeutics Performance
Assessing Summit Therapeutics' fundamental ratios provides investors with valuable insights into Summit Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Summit Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 39.4 K | 41.4 K | |
| Return On Tangible Assets | (3.06) | (2.91) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (3.03) | (2.88) | |
| Return On Equity | (7.91) | (7.52) |
Things to note about Summit Therapeutics PLC performance evaluation
Checking the ongoing alerts about Summit Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Summit Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Summit Therapeutics is way too risky over 90 days horizon | |
| Summit Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (614.93 M) with profit before overhead, payroll, taxes, and interest of 705 K. | |
| Summit Therapeutics PLC currently holds about 121.97 M in cash with (76.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Summit Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 84.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Alarm bells ringing as EV transition hits UK auto industry |
- Analyzing Summit Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Summit Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Summit Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Summit Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Summit Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Summit Therapeutics' stock. These opinions can provide insight into Summit Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.